AST SpaceMobile is moving from demos to putting real satellites in orbit to bring phone service to regular smartphones in places where towers can’t reach. Big carrier tie-ups and early government work add credibility, but the plan still hinges on flawless launches and smooth rollout in a crowded satellite race.Read more

IonQ is pulling ahead in the race to turn quantum computing from lab work into real customer work, with growing demand and a broader push into related technologies like networking and manufacturing. But the market already treats it like a sure long-term winner, so even a small stumble in execution or the tech roadmap could hit the stock hard.Read more

Rigetti is starting to look less like a science project and more like a real supplier, with early signs that customers are actually buying its quantum machines and using its cloud access. The catch: the company is still burning cash and has to hit tough technical goals, so even small stumbles could hit confidence fast.Read more

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Rating: Buy / Quality recovery compounder Style: Mid-cap consumer compounder with cyclical film-slate exposure Core debate: Is Kinepolis just a movie-theatre operator in a structurally challenged industry, or is it a premium cinema platform with better economics, stronger pricing power, and more durable cash generation than the market gives it credit for? Executive view Kinepolis is not a “cinema recovery trade” in the simple sense.Read more

Rating: Speculative / Venture-style public equity Style: Pre-revenue aerospace development story Core debate: Is Horizon Aircraft a differentiated eVTOL platform with a more practical mission profile than many peers, or is it still too early, too capital-intensive, and too uncertain to justify meaningful equity upside today? Executive view Horizon Aircraft is not an established aerospace manufacturer.Read more

Rating: Speculative Buy / High-risk value Style: Leveraged offshore E&P recovery Core debate: Is Kosmos just another debt-heavy small-cap oil and gas producer, or is it an underappreciated offshore cash-flow story with improving production, falling costs, and meaningful equity upside if management keeps deleveraging? Executive view Kosmos is not a “quality compounder” in the way Prysmian or Quanta are.Read more

Rating: High-Quality Compounder / Buy on pullbacks Style: Infrastructure-led secular grower Core debate: Is Quanta simply an expensive contractor riding an unusually strong capex cycle, or is it the best-positioned execution platform for a multi-year grid, electrification, and AI-power buildout that deserves a premium multiple? Executive view Quanta is one of the clearest “picks-and-shovels” beneficiaries of the U.S. power infrastructure supercycle.Read more

Rating: Buy / Quality Cyclical Growth Style: Aerospace OEM with backlog-driven visibility and multi-segment optionality Core debate: Is Embraer simply a smaller aircraft manufacturer benefiting from an aerospace upcycle, or is it a niche aerospace platform with durable competitive positions, improving margins, and an unusually attractive backlog-to-revenue profile? Executive view Embraer looks increasingly like one of the more attractive ways to invest in aerospace without taking full exposure to the execution problems and balance-sheet complexity of the largest airframers.Read more